These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35502786)

  • 1. Coverage of New Drugs in Medicare Part D.
    Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
    Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare Part D Protected-Class Policy Is Associated With Lower Drug Rebates.
    Kakani P; Kyle MA; Chandra A; Maini L
    Health Aff (Millwood); 2024 Oct; 43(10):1420-1427. PubMed ID: 39374459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013.
    Stuart BC; Tom SE; Choi M; Johnson A; Sun K; Qato D; Obi EN; Zacker C; Park Y; Arcona S
    Am J Manag Care; 2018 Jun; 24(6):e175-e182. PubMed ID: 29939507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
    Socal MP; Ezebilo I; Bai G; Anderson GF
    Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Formulary Exclusions and Restrictions for Opioid Alternatives With Opioid Prescribing Among Medicare Beneficiaries.
    Rao T; Kiptanui Z; Dowell P; Triebwasser C; Alexander GC; Harris I
    JAMA Netw Open; 2020 Mar; 3(3):e200274. PubMed ID: 32119095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare Part D Plans Greatly Increased Utilization Restrictions On Prescription Drugs, 2011-20.
    Joyce G; Blaylock B; Chen J; Van Nuys K
    Health Aff (Millwood); 2024 Mar; 43(3):391-397. PubMed ID: 38437610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
    Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
    Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
    Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
    Panzer AD; Ingham M; Martin S; Chambers JD
    J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
    [No Abstract]   [Full Text] [Related]  

  • 14. Medicare Part D roulette: potential implications of random assignment and plan restrictions.
    Patel RA; Walberg MP; Woelfel JA; Amaral MM; Varu P
    Medicare Medicaid Res Rev; 2013; 3(2):. PubMed ID: 24753963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients' access to 2018 FDA-approved drugs 1 year post approval.
    Panzer AD; Margaretos NM; Bridger N; Osani MC; Lai RC; Chambers JD
    Am J Manag Care; 2022 Apr; 28(4):e153-e156. PubMed ID: 35420754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.
    Lin DH; Jones CM; Compton WM; Heyward J; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket M; Porter L; Tierce JC; Alexander GC
    JAMA Netw Open; 2018 Jun; 1(2):e180235. PubMed ID: 30646077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicare Part D and nursing home residents.
    Stevenson DG; Huskamp HA; Keating NL; Newhouse JP
    J Am Geriatr Soc; 2007 Jul; 55(7):1115-25. PubMed ID: 17608889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare Part D formulary coverage since program inception: are beneficiaries choosing wisely?
    Jackson EA; Axelsen KJ
    Am J Manag Care; 2008 Nov; 14(11 Suppl):SP29-35. PubMed ID: 18991478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
    Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
    J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coverage for hepatitis C drugs in Medicare Part D.
    Jung JK; Feldman R; Cheong C; Du P; Leslie D
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.